ABSTRACT
Background Excessive alcohol consumption has been associated with increased risk of atrial fibrillation, though the underlying mechanisms remain unclear. An enlarged left atrium and impaired left atrial function may lead to atrial fibrillation. The association of alcohol consumption with structural and functional left atrial measures, however, has received limited attention.
Methods We studied a subset of 515 participants from the PREDIMED-Plus trial, a Spanish ongoing, multi-center randomized trial testing an intensive life weight loss intervention (ILI) with an energy reduced Mediterranean diet and physical activity promotion versus usual care and ad libitum Mediterranean diet recommendations for the primary prevention of cardiovascular disease in adults with the metabolic syndrome. Participants underwent transthoracic echocardiography (TTE) at baseline, year 3, and year 5 of the study. Outcomes of interest included volumetric (volume index) and functional (reservoir, conduit, and contractile strains) measures of the left atrium. Alcohol consumption was calculated through the use of validated food frequency questionnaires repeatedly collected every year and presented as drinks consumed per day (1 drink = 14 grams of alcohol). Confounder-adjusted multiple linear regression and mixed models were used to estimate the association of alcohol consumption (at baseline and over 5-years of follow-up) with left atrial volume and function at baseline and over the 5-year follow-up.
Results Mean alcohol consumption among 515 eligible participants (mean age: 65 years, 40% female) was 1.6 drinks/day. Cross-sectionally, higher alcohol consumption (modeled in 1 drink/day increases) was associated with larger left atrial volume (0.6 ml/m2, 95% CI 0.2, 1.1) and lower left atrial reservoir and contractile strain (-0.4%, 95% CI -0.8, 0.0, and -0.4, 95% CI -0.7, -0.1). Baseline alcohol consumption was not associated with changes in left atrial structure and function, but an increase in alcohol consumption (per 1 drink/day increase) during follow-up was associated with left atrial enlargement (0.7 mL/m2, 95% CI 0.2, 1.2) and, to a lesser extent, left atrial strain worsening (-0.3%, 95% CI -0.8, 0.2) over 5 years.
Conclusion In a population at high risk of cardiovascular disease, an increase of alcohol consumption was associated with left atrial volume enlargement and worsening atrial function, suggesting mechanistic information about potential pathways linking excessive alcohol consumption with atrial fibrillation risk.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was supported by NIH/NHLBI under award number R01HL137338 and K24HL148521. The PREDIMED Plus trial was supported by the European Research Council (Advanced Research Grant 2014 2014, number 340918 awarded to M.A.M.G. as principal investigator of the trial), and by the official funding agency for biomedical research of the Spanish Government, Instituto de Salud Carlos III ([Carlos III Health Institute], Sevilla, Spain), through the Fondo de Investigación para la Salud (FIS), which is cofunded by the European Regional Development Fund PI13/00673, PI13/00492, PI13/00272, PI13/01123, PI13/00462, PI13/00233, PI13/02184, PI13/00728, PI13/01090, PI13/01056, PI14/01722, PI14/0147, PI14/00636, PI14/00972, PI14/00618, PI14/00696, PI14/01206, PI14/01919, PI14/00853, PI14/01374, PI16/00473, PI16/00662, PI16/01873, PI16/01094, PI16/00501, PI16/00533, PI16/00381, PI16/00366, PI16/01522, PI16/01120, PI17/00764, PI17/01183, PI17/00855, PI17/01347, PI17/00525, PI17/01827, PI17/00532, PI17/00215, PI17/01441, PI17/00508, PI17/01732, PI17/00926, PI19/00957, PI19/00386, PI19/00309, PI19/01032, PI19/00576, PI19/00017, PI19/01226, PI19/00781, PI19/01560, PI19/01332, PI20/01802, PI20/00138, PI20/01532, PI20/00456, PI20/00339, PI20/00557, PI20/00886, PI20/01158, the Recercaixa grant 2013ACUP00194, grants from the Consejería de Salud de la Junta de Andalucía PI0458/2013; PS0358/2016, PI0137/2018, the PROMETEO/2017/017 grant from the Generalitat Valenciana, the SEMERGEN grant and FEDER funds CB06/03.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Ethics Committee of Clinical Research of the Department of Health of the Government of Navarra, the Research Ethics Committee of the Balearic Islands, and the Basque Country Clinical Research Ethics Committee all gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Interested researchers can request PREDIMED-Plus data directly from the study. Details for data acquisition are provided here: https://www.predimedplus.com/en/project/